Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Ambys launches with $140M from series A, Takeda deal

August 8, 2018 11:02 AM UTC

Liver disease company Ambys Medicines (Redwood City, Calif.) launched on Wednesday with $140 million in funding from a series A round and an option partnership with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502).

Ambys' $60 million series A round comprises $40 million from Third Rock Ventures and the remainder from Takeda. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article